Status:
COMPLETED
Characterisation of the Human Carboxylesterase 1 (CES1) Mutations in Thailand
Lead Sponsor:
University of Oxford
Collaborating Sponsors:
South East Asia Infectious Disease Clinical Research Network
Conditions:
Metabolic Disease
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
The aim of this study is to evaluate the conversion of OP to OC in individual X and the family member of individual X. The investigators hypothesize that one or more of the single nucleoprotein polymo...
Detailed Description
Oseltamivir is beneficial in the treatment of mild influenza. When given by mouth, oseltamivir phosphate (OP), the parent drug, is rapidly absorbed and rapidly converted to oseltamivir carboxylate (OC...
Eligibility Criteria
Inclusion
- Signed informed consent
- Healthy family member of individual X and individual X
- Aged between 18 and 70, inclusive.
Exclusion
- known allergy to oseltamivir
- any underlying illness that is considered a risk to the health of the individual
- pregnant
- breast feeding
- creatinine clearance \< 30 mL/min calculated by the Cockcroft Gault formula: CrCl (ml/min) = (140-age) x Wt in kg / creatinine mg/dL x 72, for females, the result is multiplied by 0.85.
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT01443806
Start Date
July 1 2011
End Date
December 1 2012
Last Update
June 27 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Faculty of Tropical medicine,Mahidol University
Bangkok, Thailand, 10400